SMTL ID : 6x4t.2 (1 other biounit)

Crystal structure of ICOS-L in complex with Prezalumab and VNAR domain

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.15 Å

Oligo State

hetero-1-1-1-1-mer

Ligands

1 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG-NAG.1: 6 residues within 4Å: Chain B: N.157, T.159, D.160, I.189, S.194, I.197 No protein-ligand interaction detected (PLIP)

4 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.2: 5 residues within 4Å: Chain B: M.12, N.121, V.124, Q.208, L.210 2 PLIP interactions: 2 interactions with chain B Hydrogen bonds: B:N.121, B:Q.208 NAG.3: 2 residues within 4Å: Chain B: N.86, T.88 1 PLIP interactions: 1 interactions with chain B Hydrogen bonds: B:N.86 NAG.4: 3 residues within 4Å: Chain B: N.170, T.172, R.188 3 PLIP interactions: 3 interactions with chain B Hydrogen bonds: B:N.170, B:T.172, B:R.188 NAG.5: 5 residues within 4Å: Chain B: Y.154, L.163, E.202, Q.207, N.209 1 PLIP interactions: 1 interactions with chain B Hydrogen bonds: B:N.209

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Rujas, E. et al., Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies. Nat Commun (2020)

Release Date

2020-10-14

Peptides

Prezalumab Fab Heavy chain: A
ICOS ligand: B
Prezalumab Fab Light chain: C
VNAR: D

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

B
C

C
E

D
N

Prezalumab Fab Heavy chain

ICOS ligand

Prezalumab Fab Light chain

VNAR

Related Entries With Identical Sequence